35,610,000 SHARES of Common Stock, 4,390,000 pre-funded warrants (exercisable for 4,390,000 shares) and 40,000,000 class B Warrants (exercisable for 40,000,000 shares) of TITAN PHARMACEUTICALS, INC.Underwriting Agreement • October 18th, 2019 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
The undersigned, Titan Pharmaceuticals, Inc., a company incorporated under the laws of Delaware (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
Titan Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company, as Warrant Agent Class B Warrant Agency Agreement Dated as of October 16, 2019 CLASS B WARRANT AGENCY AGREEMENTClass B Warrant Agency Agreement • October 18th, 2019 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
CLASS B WARRANT AGENCY AGREEMENT, dated as of October 16, 2019 (“Agreement”), between Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”).
